MX2023000092A - Conjugado de galnac y saponina, composicion terapeutica que comprende dicho conjugado y un conjugado de galnac-oligonucleotido . - Google Patents

Conjugado de galnac y saponina, composicion terapeutica que comprende dicho conjugado y un conjugado de galnac-oligonucleotido .

Info

Publication number
MX2023000092A
MX2023000092A MX2023000092A MX2023000092A MX2023000092A MX 2023000092 A MX2023000092 A MX 2023000092A MX 2023000092 A MX2023000092 A MX 2023000092A MX 2023000092 A MX2023000092 A MX 2023000092A MX 2023000092 A MX2023000092 A MX 2023000092A
Authority
MX
Mexico
Prior art keywords
conjugate
relates
saponin
pharmaceutical composition
galnac
Prior art date
Application number
MX2023000092A
Other languages
English (en)
Spanish (es)
Inventor
Ruben Postel
Guy Hermans
Original Assignee
Sapreme Tech Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=85176234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2023000092(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sapreme Tech Bv filed Critical Sapreme Tech Bv
Priority claimed from PCT/NL2021/050384 external-priority patent/WO2021261992A1/en
Publication of MX2023000092A publication Critical patent/MX2023000092A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MX2023000092A 2020-06-24 2021-06-18 Conjugado de galnac y saponina, composicion terapeutica que comprende dicho conjugado y un conjugado de galnac-oligonucleotido . MX2023000092A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2025899 2020-06-24
NL2026442 2020-09-10
PCT/NL2021/050384 WO2021261992A1 (en) 2020-06-24 2021-06-18 Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate

Publications (1)

Publication Number Publication Date
MX2023000092A true MX2023000092A (es) 2023-04-20

Family

ID=85176234

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000092A MX2023000092A (es) 2020-06-24 2021-06-18 Conjugado de galnac y saponina, composicion terapeutica que comprende dicho conjugado y un conjugado de galnac-oligonucleotido .

Country Status (10)

Country Link
US (1) US20230263897A1 (https=)
EP (2) EP4438125A3 (https=)
JP (1) JP2023532040A (https=)
KR (1) KR20230043114A (https=)
CN (2) CN116234582A (https=)
AU (1) AU2021295358B2 (https=)
CA (1) CA3183885A1 (https=)
ES (1) ES3002193T3 (https=)
IL (1) IL299357A (https=)
MX (1) MX2023000092A (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021001646A2 (en) * 2019-07-02 2021-01-07 Argonaute RNA Limited Apolipoprotein b antagonist
WO2025016444A1 (en) * 2023-07-20 2025-01-23 Shanghai Argo Biopharmaceutical Co., Ltd. Compositions and methods for inhibiting expression of pd-l1
CN116655715B (zh) * 2023-07-27 2023-10-20 北京炫景瑞医药科技有限公司 一种GalNAc衍生物、缀合物、组合物以及它们的用途
CN116854754B (zh) * 2023-09-01 2023-12-12 北京悦康科创医药科技股份有限公司 一种含有核糖环或其衍生结构的GalNAc化合物及其寡核苷酸缀合物
WO2025090612A1 (en) * 2023-10-27 2025-05-01 Wisconsin Alumni Research Foundation Lipid nanoparticles formed by lipidoids for efficient delivery of nucleotide drugs and biologics

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041310A1 (en) * 2002-11-08 2004-05-21 Danmarks Fødevareforskning Preparation of chemically well-defined carbohydrate dendrimer conjugates
EP1623715B1 (en) * 2004-07-13 2012-09-19 Charité - Universitätsmedizin Berlin A composition comprising a pharmacologically active agent coupled to a target cell specific component, and a saponin
WO2008007941A1 (en) * 2006-07-10 2008-01-17 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Gainac specific binding molecules and uses thereof
WO2011054811A1 (en) 2009-11-03 2011-05-12 Santaris Pharma A/S Rna antagonists targeting hsp27 combination therapy
WO2011141703A1 (en) * 2010-05-12 2011-11-17 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b
CA2800911A1 (en) * 2010-06-11 2011-12-15 University Of Georgia Research Foundation, Inc. Immunogenic vaccine
US20150024037A1 (en) * 2012-02-16 2015-01-22 The University Of Toledo Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making
DK2992098T3 (da) * 2013-05-01 2019-06-17 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
AR100516A1 (es) * 2014-05-19 2016-10-12 Pfizer Compuestos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol sustituidos como agentes de direccionamiento al asgpr
CN106795200B (zh) * 2014-10-10 2020-06-19 豪夫迈·罗氏有限公司 Galnac亚磷酰胺、其核酸缀合物及其用途
EP3514240A1 (en) * 2018-01-18 2019-07-24 Freie Universität Berlin Novel uses of a saponin and method for its isolation
SG11202106603UA (en) * 2018-12-21 2021-07-29 Sapreme Tech Bv Biologically active cluster of molecules

Also Published As

Publication number Publication date
ES3002193T3 (en) 2025-03-06
AU2021295358A9 (en) 2023-06-29
EP4171641A1 (en) 2023-05-03
EP4171641B1 (en) 2024-10-30
JP2023532040A (ja) 2023-07-26
EP4438125A3 (en) 2024-12-25
US20230263897A1 (en) 2023-08-24
AU2021295358A1 (en) 2023-02-16
IL299357A (en) 2023-02-01
EP4438125A2 (en) 2024-10-02
KR20230043114A (ko) 2023-03-30
AU2021295358B2 (en) 2026-01-22
CN120586078A (zh) 2025-09-05
CA3183885A1 (en) 2021-12-30
CN116234582A (zh) 2023-06-06
EP4171641C0 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
MX2023000092A (es) Conjugado de galnac y saponina, composicion terapeutica que comprende dicho conjugado y un conjugado de galnac-oligonucleotido .
EP4591938A3 (en) Conjugate of saponin, oligonucleotide and galnac
ES3062897T3 (en) Compositions and methods of treating muscle dystrophy
NZ778378A (en) Improved cell-targeting binding molecule
ES2847288T3 (es) Péptidos derivados de preS hidrófobos modificados del virus de la hepatitis B (VHB) y su uso como vehículos para el suministro específico de compuestos al hígado
Sun et al. Bisphosphonates for delivering drugs to bone
EP4596052A3 (en) Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof
AU2017389094B2 (en) Aptamer-drug conjugate and use thereof
BR112014026730A2 (pt) conjugados fármaco-ligante de dr5
PE20250839A1 (es) Proteinas y conjugados de union al receptor de transferrina
JP2016056209A5 (https=)
BR112021025394A2 (pt) Derivados de antraciclina, conjugados de fármaco e molécula de ligação ao alvo, uso de conjugado de fármaco e molécula de ligação ao alvo, método de tratamento de uma doença em um paciente em necessidade de tratamento, e composição farmacêutica
EP4529953A3 (en) Conjugate of saponin, oligonucleotide and galnac
CN115666653A (zh) 抗体-药物缀合物
JP2023532040A5 (https=)
WO2022194988A3 (en) B-lymphocyte specific amatoxin antibody conjugates
MX2022016485A (es) Derivados de saponina con ventana terapeutica mejorada.
JP2018521977A5 (https=)
EP3218010B1 (en) Polymer composed of repeat units having a biologically active molecule attached thereto via a ph-sensitive bond
JP2022516032A (ja) 抗体－薬物複合体
Kwon et al. PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation
JP2026502232A (ja) エキサテカン誘導体を含むｕＰＡＲＡＰを標的とする抗体薬物複合体
BRPI0414026A (pt) composição para a prevenção/tratamento de infecções de hbv e doenças mediadas por hbv e método para preparar um medicamento para o tratamento terapêutico de hepatite b
BR112023026735A2 (pt) Conjugado, composto de conector-fármaco, uso de um composto de conector-fármaco, e, composição farmacêutica
WO2023107893A3 (en) Treatment of neurodegenerative diseases through the inhibition of ataxin-2